Cilcare Revenue and Competitors
Estimated Revenue & Valuation
- Cilcare's estimated annual revenue is currently $7.8M per year.
- Cilcare's estimated revenue per employee is $201,000
Employee Data
- Cilcare has 39 Employees.
- Cilcare grew their employee count by 8% last year.
Cilcare's People
Name | Title | Email/Phone |
---|
Cilcare Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $46.2M | 230 | 5% | N/A | N/A |
#2 | $43.8M | 218 | 21% | N/A | N/A |
#3 | $57.1M | 284 | 26% | N/A | N/A |
#4 | $24.5M | 122 | 3% | N/A | N/A |
#5 | $52.9M | 263 | 13% | N/A | N/A |
#6 | $24.7M | 123 | 13% | N/A | N/A |
#7 | $1.8M | 18 | 0% | $114.3M | N/A |
#8 | $7.2M | 36 | -20% | N/A | N/A |
#9 | $13.7M | 68 | -7% | N/A | N/A |
#10 | $7.6M | 39 | -13% | $123.9M | N/A |
What Is Cilcare?
CILcare is an R&D services company specialized in hearing disorders. On an international market, CILcare proposes to its clients to accelerate the development of their drug candidates by testing their efficacy on preclinical pharmacological models and by supporting them in the preparation of their health product development plans. If the importance of investigating tinnitus and hearing loss is pointed out, the underlying fundamental knowledge, based on animal models and the translational mindset are severely lacking. CILcare's offer fills this gap by providing means to validate hypotheses toward solutions able to prevent and to reduce hearing disorders. The company is located in Montpellier (France) and was founded in 2014 following the reorganization of the R&D of a big pharmaceutical company. CILcare is benefitting from strong expertise and an international network of clients and partners.
keywords:N/AN/A
Total Funding
39
Number of Employees
$7.8M
Revenue (est)
8%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $4.2M | 40 | 21% | N/A |
#2 | $4.8M | 41 | 8% | N/A |
#3 | $6.8M | 42 | 75% | N/A |
#4 | N/A | 45 | 36% | N/A |
#5 | $9M | 45 | 10% | N/A |